SCHEMBL200872

SCHEMBL200872

CCOC(=O)C(C)(C)Oc1ccc(OCC(C2CCCCC2)C2(c3ccc(Cl)cc3)N=c3cc(F)c(F)cc3=N2)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.42
CYP3A4 P08684 2/20 0.42
ABCB11 O95342 1/20 0.42
CYP1A2 P05177 1/20 0.42
TSHR P16473 1/20 0.42
HTR2A P28223 1/20 0.42
PMP22 Q01453 1/20 0.42
FBP1 P09467 6/20 0.36
LMNA P02545 1/20 0.35
HSD11B1 P28845 1/20 0.34
CNR1 P21554 2/20 0.33
ALDH1A1 P00352 1/20 0.33
NR1H4 Q96RI1 4/20 0.32
CYP2C9 P11712 2/20 0.32
KDR P35968 1/20 0.31
OPRK1 P41145 1/20 0.31
CYP2D6 P10635 1/20 0.30
KCNH2 Q12809 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL198731 0.89 PPARA (0.41) PPARACYP3A4ABCB11CYP1A2TSHR
SCHEMBL200871 0.85 PPARA (0.42) PPARACYP3A4ABCB11CYP1A2TSHR
SCHEMBL198389 0.83 PPARA (0.42) PPARACYP3A4CYP1A2TSHRLMNA
SCHEMBL198481 0.80 PPARA (0.36) PPARACYP3A4CYP1A2CNR1CYP2D6
SCHEMBL1842335 0.77 PPARA (0.47) PPARACYP3A4ABCB11CYP1A2TSHR
SCHEMBL198629 0.77 NR1H4 (0.40) CYP3A4NR1H4CYP2C9CYP2D6KCNH2
SCHEMBL1840370 0.76 ABCB11 (0.37) PPARACYP3A4ABCB11CYP1A2TSHR
SCHEMBL1843200 0.76 PPARA (0.37) PPARACYP3A4CYP1A2NR1H4CYP2C9
SCHEMBL197542 0.76 NR1H4 (0.51) CYP3A4NR1H4CYP2C9CYP2D6KCNH2
SCHEMBL1839730 0.76 PPARA (0.41) PPARACYP3A4ABCB11CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088930-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-01-03 US disclosed
US-20100063101-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063101-A1 NEW BENZIMIDAZOLE DERIVATIVES CYP3A7, ECI1, CYP2B6 PPARA 322/4885CYP3A4 4/4885ABCB11 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.